The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Update on Locally Advanced Breast Cancer
Abstract
Learning Objectives: After completing this course, the reader will be able to: Discuss the heterogeneity of locally advanced breast cancer. Explain the rationale for the multidisciplinary coordination of care for patients with locally advanced breast cancer. Identify the current standard of care for the treatment of locally advanced breast cancer. Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Locally advanced breast cancer remains a clinical challenge as the majority of patients with this diagnosis develop distant metastases despite appropriate therapy. Patients with locally advanced disease encompass a wide range of clinical scenarios including advanced primary tumors (stage T4), advanced nodal disease (fixed axillary nodes or involvement of ipsilateral supraclavicular, infraclavicular, or internal mammary nodes), and inflammatory carcinomas. The prognoses of women with locally advanced breast tumors are also heterogeneous and depend on tumor size, extent of lymph node involvement, and the presence or absence of inflammatory carcinoma. Women with locally advanced disease require multimodal therapy, and coordinated treatment planning among the medical oncologist, surgical oncologist, and radiation oncologist is necessary to optimize patient care. In this article, the epidemiology, evaluation, prognostic factors, and treatment for locally advanced breast cancer are discussed. Inflammatory cancer is also reviewed, but is considered separately due to its distinct biology and clinical behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For women with HER-2 positive metastatic breast cancer, treatment with trastuzumab in combination with chemotherapy can improve survival [ 34 ].”
Background
Cited by
Braman, N. M., Etesami, M., Prasanna, P., Dubchuk, C., Gilmore, H., Tiwari, P., Plecha, D., & Madabhushi, A. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0846-1 · Cited by 632
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
“Inoperable LABC is a heterogeneous designation encompassing a range of clinical situations from neglected low-grade ERpositive breast cancers to rapidly progressing usually ER-negative disease [30–33].”
BackgroundSelf-citationDrug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.08.009 · Cited by 338
Self-citationQuantitative Ultrasound in Soft Tissues
(2013) · Springer eBooks · doi:10.1007/978-94-007-6952-6 · Cited by 302
Metadata
- Authors
- Giordano, S. H.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-01
- Volume
- 8
- Issue
- 6
- Pages
- 521-530
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2159610922
- Cited by
- 223
- References
- 1
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on Locally Advanced Breast Cancer. https://app.cochat.ai/papers/10.1634/theoncologist.8-6-521
- The paper
- Giordano, S. H. (2003). Update on Locally Advanced Breast Cancer. The Oncologist. https://doi.org/10.1634/theoncologist.8-6-521
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.